Rare breast tumor

Rare breast tumors encompass a heterogeneous group of uncommon neoplasms arising in the breast tissue that do not fall into the typical categories of invasive ductal or lobular carcinoma. This Orphanet classification (ORPHA:180250) serves as a broad grouping for various rare histological subtypes of breast tumors, which may include entities such as secretory carcinoma, adenoid cystic carcinoma of the breast, metaplastic carcinoma, phyllodes tumors, angiosarcoma of the breast, and other exceptionally uncommon breast neoplasms. These tumors primarily affect the breast but may also involve regional lymph nodes and, in malignant cases, can metastasize to distant organs including the lungs, bones, liver, and brain. Clinical presentation varies depending on the specific tumor subtype but commonly includes a palpable breast mass, changes in breast shape or skin texture, nipple discharge, or axillary lymphadenopathy. Some rare breast tumors may behave indolently with an excellent prognosis (such as adenoid cystic carcinoma), while others can be highly aggressive (such as inflammatory breast cancer variants or angiosarcoma). Diagnosis typically requires imaging studies including mammography and ultrasound, followed by histopathological examination of biopsy specimens, often supplemented by immunohistochemistry and molecular profiling to accurately classify the tumor subtype. Treatment approaches depend on the specific histological type, stage, and molecular characteristics of the tumor. Options generally include surgical resection (lumpectomy or mastectomy), radiation therapy, chemotherapy, and in some cases targeted therapies or hormonal therapy if the tumor expresses relevant receptors. Due to the rarity of these tumors, evidence-based treatment guidelines are often limited, and management decisions frequently rely on case series, expert opinion, and extrapolation from more common breast cancer subtypes. Multidisciplinary care at specialized centers with experience in rare breast tumors is strongly recommended to optimize outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Rare breast tumor